Lewis Gazzard

Materials Science · Physical Sciences

16h-index1.1kcitations66works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Crystallization and Solubility Studies(18), X-ray Diffraction in Crystallography(18), Colorectal Cancer Treatments and Studies(12), Cancer therapeutics and mechanisms(11), DNA Repair Mechanisms(7)

Publications66 total

Targeting PTPN22 at Nonorthosteric Binding Sites─A Fragment Approach
ACS Omega·2026Open Access
Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1
ACS Medicinal Chemistry Letters·2024· 12 citedOpen Access
Identification of Potent and Orally Bioavailable Spirocyclic Imidazoisoindole Inhibitors of Indoleamine Dioxygenase 1 and Tryptophan Dioxygenase 2
SSRN Electronic Journal·2024Open Access
Structure-Based Design and Evaluation of Reversible KRAS G13D Inhibitors
ACS Medicinal Chemistry Letters·2023· 6 citedOpen Access
Supplemental Figure 4 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 8 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Data from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 4 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 8 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 1 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 6 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 2 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 3 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 5 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 7 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 3 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Data from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 2 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 7 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 5 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Shiva Malek(18), Jason Halladay(17), Jennifer Epler(17), Elizabeth Blackwood(17), Ivana Yen(17), Diana Jakubiak(15), Marie Evangelista(15), Michael Flagella(15), Gary Cain(14), Judi Ramiscal(14), Sharon Yee(14), Jonathan Choi(13), Kaska Kowanetz(13), Kenton Wong(13), Peter K. Jackson(13), Hank La(12), Tom O’Brien(12), Karen Williams(12), Rohan Mendonca(11), Amy Gustafson(11)